Kilitch Drugs (India) Limited, a pharmaceutical company, has announced a delay in the finalization of its Rights Issue allotment process. The company has pushed back the date for finalizing the basis of allotment and the allotment schedule from August 22, 2025, to August 25, 2025.

Rights Issue Details

The Rights Issue, which was initially approved by the company's Board of Directors on July 12, 2025, involves:

• Offering 13,98,463 equity shares
• Face value of Rs. 10.00 per share
• Issue price of Rs. 357.00 per share
• Total aggregation of Rs. 4,992.51 lakhs (approximately Rs. 49.93 crores)
• Rights ratio: 2 rights equity shares for every 23 fully paid-up equity shares held

Eligible shareholders, as determined on the record date of July 15, 2025, are entitled to participate in this Rights Issue.

Reason for Postponement

According to the company's official communication, the postponement decision was made in consultation with the National Stock Exchange of India Limited (NSE), which is the designated stock exchange for this issue, and the Registrar to the Issue. The company stated that the finalization and allotment process is currently underway and requires additional time.

Impact on Investors

This three-day delay may affect the timeline for investors expecting to receive their allotted shares. However, the company has not provided any information regarding changes to other key dates in the Rights Issue process.

Company Statement

Mukund Mehta, Managing Director of Kilitch Drugs (India) Limited, signed the official intimation to the stock exchanges regarding this postponement. The company has requested the stock exchanges to acknowledge and record this update.

Investors and market participants are advised to stay updated with any further announcements from the company regarding the Rights Issue process.

Note: This article is based on the latest available information as of August 22, 2025, and investors should consult official company communications for the most current updates.

Kilitch Drugs (India) Limited, a prominent player in the pharmaceutical industry, has announced impressive financial results for the first quarter, demonstrating strong growth across key metrics.

Financial Highlights

The company's consolidated performance for Q1 showcases significant improvements:

Revenue Growth

Kilitch Drugs witnessed a robust 28.96% year-on-year increase in consolidated net sales, which rose to ₹4,313.98 lakhs from ₹3,345.16 lakhs in the corresponding quarter of the previous year. This growth reflects the company's strong market position and effective sales strategies.

Profitability Surge

The company's bottom line saw a significant improvement, with consolidated net profit increasing to ₹226.25 lakhs, marking a 130.94% increase from ₹97.97 lakhs in the same quarter of the previous year. This substantial profit growth underscores Kilitch Drugs' operational efficiency and cost management efforts.

Improved Operational Efficiency

Kilitch Drugs' EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) stood at ₹582.20 lakhs, up by 37.55% from ₹423.27 lakhs in the same period last year. The EBITDA margin also improved to 13.50% from 12.70%, indicating enhanced operational efficiency and better cost control measures.

Standalone Performance

On a standalone basis, Kilitch Drugs reported equally impressive results:

• Net sales increased by 2.10% to ₹3,412.20 lakhs
• Net profit after tax surged by 18.26% to ₹479.41 lakhs
• EBITDA grew by 6.85% to ₹706.70 lakhs
• EBITDA margin improved to 20.71% from 19.81%

Future Outlook

The company's board has approved a rights issue of 13,968,463 equity shares at an issue price of ₹357 per share, aggregating to ₹4,992.51 lakhs. This move is expected to strengthen Kilitch Drugs' financial position and support its growth initiatives.

Kilitch Drugs' strong Q1 performance, characterized by substantial revenue growth and profitability improvement, positions the company well for sustained growth in the pharmaceutical sector. Investors and stakeholders will likely keep a close watch on the company's future quarters to see if this positive momentum continues.